Articles tagged with Prostate Cancer
Researchers found that adding hormone-suppression therapy to radiotherapy for advanced prostate cancer significantly improved five-year disease-free survival rates. The study involved 415 patients, with those receiving combined therapy showing a substantial increase in overall survival rates.
A study finds that PSA testing led to a 29% and 44% overdiagnosis rate among white and black men, respectively. The increased incidence was partly due to unnecessary biopsies and side effects from treatment.
A new study conducted in New Zealand found no increased risk of prostate cancer among men who had undergone vasectomy. The study, which interviewed over 2,200 men, suggests that vasectomy does not pose a biological risk for prostate cancer.
A new test measures the ratio of cathepsin B to inhibitor stefin A in prostate tissue, revealing differences in tumors not visible under the microscope. The test can identify biologically aggressive and less aggressive forms of cancer, guiding treatment decisions for patients.
Researchers at Temple University discovered that the Rb2 gene's lack of expression could be an early indicator of prostate cancer. A study found lower expression levels of Rb2 in prostate tissue as it progresses from normal to cancerous, suggesting its potential use as a diagnostic marker.
This study estimates the direct and indirect costs of prostate cancer in California for 1998, finding that hospitalization costs account for almost three-fifths of total costs. Prostate cancer adds significant costs to patients with comorbid conditions, such as heart disease or respiratory illness.
A new study by Columbia University Irving Medical Center reveals significant differences in PSA (Prostate-Specific Antigen) and PSAD (Prostate-Specific Antigen Density) test measurements between Caucasian and Hispanic men. The study found that while PSAD can accurately predict cancer risk in Caucasians, it is less effective in Hispanic...
Researchers discovered a set of 511 genes that distinguish four groups of patients with benign prostatic hyperplasia (BPH), including those with symptoms and cancer. The findings suggest a potential link between BPH and prostate cancer, as well as a genetic 'field effect' in individuals with prostate cancer.
A recent study has challenged the long-held notion that African-Americans with prostate cancer have a poorer prognosis than their white counterparts. Researchers found that, when treated within clinical trial settings, African-American patients survived for an average of 15 months, comparable to 14-month survival rates for whites.
The study found patients who received the high-dose regimen had significantly longer overall and disease-free survival rates than those who received a lower dose. The company plans to initiate a Phase III trial of GVAX prostate cancer vaccine in the first half of 2003.
Researchers found that freezing cancer cells in test tubes increases their vulnerability to bleomycin, a potent anti-cancer drug. This combination therapy may lead to a powerful new form of cancer treatment targeting malignant cells while leaving healthy tissue unharmed.
Researchers at UIC are testing a new vaccine for advanced prostate cancer, targeting patients with a specific immune type. The vaccine uses a fragment of the protein PSA to stimulate the immune system and destroy tumor cells.
Hopkins researchers identified a nine-fold increase in expression of the AMACR gene in prostate cancers, making it a promising early marker and potential drug target. Overexpression patterns were also found in precancerous lesions, highlighting the gene's potential for non-invasive detection and prevention.
Researchers are developing a new method to improve the diagnosis of prostate cancer by using contrast-enhanced ultrasound. The study aims to identify areas in the prostate with more blood vessels, allowing for targeted biopsies and potentially reducing the number of unnecessary procedures.
Researchers found that a combination of targeted therapies can effectively inhibit tumor growth in prostate cancer. Using different drugs after resistance occurred inhibited tumor growth, suggesting multiple treatments may be needed to manage the disease. This approach is similar to how advanced breast cancer is treated today.
Prostate cancer tumors produce factors that inhibit dendritic cell growth and induce apoptosis, explaining immunological non-responsiveness in advanced patients. Stimulating dendritic cell growth is a promising area for future prostate cancer therapies.
The grant will allow Rush to increase awareness among African-American men aged 50+, who are disproportionately affected by prostate cancer. The organization plans to conduct free screenings and refer patients to local doctors or Rush after diagnosis.
Researchers at the University of Michigan have identified a gene, AMACR, which triggers production of a specific enzyme involved in fat metabolism. The protein is detected in over 95% of localized prostate cancer cells and shows high sensitivity and selectivity ratings for diagnostic purposes.
Researchers have identified new markers for prostate and colon cancers, as well as a potential tumor suppressor gene. TIG1 was found to be expressed in normal prostate tissue but not malignant tumors, suggesting it may play a role in cancer progression.
Men treated with ADT experienced increased complications, including impotence (80%), breast swelling, and hot flashes. Despite this, many reported feeling free of cancer after treatment.
A recent study published in the Mayo Clinic Proceedings found that daily NSAID use reduced prostate cancer risk by up to 60% in men aged 60 and older. The study, which followed 1,362 Caucasian men for an average of five and a half years, suggests that the beneficial effect may increase with age.
Late-stage prostate cancer unresponsive to hormone therapy due to hypermethylation of estrogen receptor genes. A new study suggests that demethylating agents could restore effectiveness of hormone therapy by reversing methylation.
Two new studies published in the Journal of the National Cancer Institute suggest that frequent tomato product consumption may reduce prostate cancer risk. Additionally, researchers found a possible role for the Ras gene in neuroblastoma regression and increased levels of GRP growth factor in head and neck cancers.
Evidence suggests PSA screening may not significantly reduce prostate cancer mortality rates. Large-scale randomized controlled trials are necessary to confirm these findings and provide clarity on the effectiveness of PSA screening at a population level.
A new PET tracer, 11C-acetate, has been found to detect prostate cancer earlier and more accurately than 18F-FDG PET. This breakthrough may enable the detection of cancers that are currently undetectable by conventional methods.
A diagnostic scan called capromab pendetide immunoscintigraphy can detect recurrent disease if it is localized to the area of prior prostate surgery or has spread to other parts of the body. The study found that this imaging tool is more sensitive than CT and bone scans in identifying the site and extent of disease recurrence.
A new study finds that prostate-specific antigen (PSA) is clinically unreliable for diagnosing prostate cancer, with low levels not meaningfully related to the disease. Prostate cancer is being over-diagnosed and over-treated due to a misconception about PSA's role in the disease.
A new prostate cancer vaccine developed at Duke University Medical Center has shown promising results, boosting the patient's immune system to fight cancer. The vaccine, made from the patient's own dendritic cells, causes no adverse side effects and activates T cell responses against tumor cells.
The Selenium and Vitamin E Cancer Prevention Trial, or SELECT, is the largest-ever clinical trial for prostate cancer prevention. The study aims to investigate whether taking selenium and vitamin E supplements can prevent prostate cancer in men of all races and ethnic backgrounds.
Scientists have identified a specific gene, RNASEL, in the HPC1 region linked to hereditary prostate cancer in some families. The study found mutations that inactivate this cellular self-destruct mechanism, explaining why some prostate cells become cancerous.
Researchers have identified matrix metalloproteinases as a key player in the spread of prostate cancer to the bone, offering a new target for treatment. Additionally, a genetic marker may be useful in predicting survival rates for patients with diffuse large B-cell lymphoma, while oral contraceptive use has been found to reduce ovarian...
Fewer than half the physicians surveyed thought early detection would reduce mortality rates. Routine screening was often offered due to perceived standard of care or fear of malpractice lawsuits.
A study by Stanford University urologist James D. Brooks confirms a direct connection between selenium and reduced risk of prostate cancer, particularly among older men with lower blood levels of the essential mineral.
Researchers at Johns Hopkins have developed a potential new screening test for prostate cancer by measuring the level of GSTP1 methylation in tissue samples. High levels of methylation were detected in 91.3% of early-stage cancers and 53.6% of precancerous lesions, suggesting its potential as an early diagnostic marker.
A new experimental drug called 2C4 has shown to significantly inhibit tumor growth in hormone-dependent and resistant prostate cancer tumors in mice. The monoclonal antibody targets the HER-2/neu protein, which controls cell growth and stimulates tumor growth.
Prostate cancer screening is a contentious issue due to its potential impact on quality of life and the need for well-informed decision-making. The article highlights the limitations of current research, including the lack of data on risk-benefit analysis and the importance of avoiding unnecessary anxiety and treatment.
A new 'double suicide gene' therapy has shown promise in treating prostate cancer by carrying pairs of fused genes directly into cancer cells and inducing self-destruction. The technique achieved "greater levels of targeted cytotoxicity" than single suicide gene therapy, with minimal toxicities reported among patients.
The rate of prostate cancer diagnosis has increased significantly, with only 3-5% of newly diagnosed patients having advanced disease. However, the impact of this shift on mortality rates is uncertain, as PSA screening can lead to over-treatment and unnecessary aggressive treatment.
Exisulind, a new selective apoptotic anti-neoplastic drug, delays disease progression in men with recurrent prostate cancer by slowing the rise of PSA levels. The study also found significant inhibition of tumor growth in mice, suggesting potential as a treatment option for advanced prostate cancer.
A new study from Massachusetts General Hospital found that medication pamidronate prevented bone loss in men with prostate cancer who received androgen-deprivation therapy. The study showed significant differences in bone mineral density between the treatment and control groups.
A large study of male physicians found that high calcium intake, particularly from dairy products, was associated with a 30-34% increased risk of prostate cancer. The authors suggest that this may be due to the suppression of vitamin D production, which is thought to protect against prostate cancer.
A computerized tool called Prostogram offers about 66% accuracy in predicting five-year prognosis following brachytherapy treatment for early-stage prostate cancer. The nomogram is based on individual factors such as PSA levels, Gleason score, and disease stage.
A study published by the American Chemical Society found that consuming three-fourths cup of tomato sauce daily for three weeks reduced DNA damage and PSA levels in 24 black volunteers with newly diagnosed prostate cancer. This suggests that eating extra tomato sauce may be beneficial to those at high risk for prostate cancer.
Researchers at U-M discovered nearly 200 genes with varying expression profiles in normal and malignant prostate tissue. The study identified new clinical biomarkers, hepsin and pim-1, which were correlated with patient prognosis and could lead to new diagnostic tests.
The study found that exisulind significantly suppressed the rise in PSA levels compared to placebo, especially in high-risk patients. Exisulind therapy also lengthened the median PSA doubling time, suggesting a delay in disease progression.
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) aims to determine if these two dietary supplements can protect against prostate cancer. The study will include 32,400 men across the US, Puerto Rico, and Canada, and will take up to 12 years to complete.
A new pilot study suggests that a combination of a low-fat diet and flaxseed supplement may be protective against prostate cancer. The researchers found significant decreases in cholesterol levels and testosterone, as well as lower proliferation rates and higher apoptosis rates in tumor cells among those on the diet.
A new study at Ohio State University found that using an extended sector biopsy technique can detect cancer in 13.5% more men than traditional methods. The additional tissue samples improved the accuracy of prostate cancer diagnoses, particularly for cancers detected inside the gland.
Researchers discovered that introducing a tiny mutation in the telomerase enzyme can trigger a DNA damage response, inducing cell-cycle arrest or cell death in human cancer cells. This approach could lead to a new therapeutic strategy for cancer treatment.
Researchers developed a new phased-array transducer system that enables electronic scanning of the prostate, reducing the need for mechanical adjustments. The design uses separate elements and adjusted signal timing to move the focus electronically.
A recent study published in the American Journal of Epidemiology found a direct positive relationship between lifetime female sexual partners and the risk of prostate cancer in middle-aged men. Men with 30 or more partners had over twice the risk of developing prostate cancer compared to those with fewer partners.
Researchers at Memorial Sloan Kettering Cancer Center have developed a new mouse model that shows gene mutations leading to 100% prostate cancer incidence. This discovery provides insight into genetic variations causing more severe forms of prostate cancer in humans.
A novel therapy employing the immune system to attack prostate cancer cells has been found to slow disease progression in some men and decrease PSA levels. The study's results show that modified dendritic cells can train lymphocytes to recognize prostate cancer cells, leading to a stronger immune response.
A University of California, San Francisco study found that the herbal supplement PC-SPES significantly reduces PSA levels in men with hormone-independent disease, providing a new treatment option. The study also shows promise for shrinking tumors and improving quality of life.
A new study from the University of North Carolina at Chapel Hill suggests that current PSA screening strategies should be changed. Testing men at ages 40 and 45, and then every two years after age 50, may prevent more deaths than waiting until age 50.
Researchers found that combining radiation therapy with androgen suppression therapy significantly reduced the risk of PSA failure in men with intermediate- and high-risk prostate cancer. The treatment showed efficacy even in low-risk patients, suggesting a potential benefit for all early-stage prostate cancer patients.
Researchers have identified three candidate regions on chromosomes 5q, 7q, and 19q that may contain genes influencing prostate cancer aggressiveness. These regions are associated with a higher Gleason score, indicating poor differentiation of tumor cells and increased risk of metastasis.
Researchers found that patients with localized prostate cancer who received higher doses of radiation lived longer and had better local control of their cancer. The study, published in the Journal of Clinical Oncology, examined data from 1560 patients treated between 1975 and 1995.
Researchers are testing two vaccines, using vaccinia and fowlpox viruses, to treat prostate cancer that has spread beyond the gland. The goal is to boost the patient's immune system and eliminate cancer cells before they become symptomatic.
Abarelix depot-M successfully suppresses testosterone levels, achieving suppression by day 8 and maintaining it from day 29 through day 85. The studies validated PRAECIS' core technology and demonstrate a potentially new treatment option for prostate cancer.